Skip to main content
IBRX
NASDAQ Life Sciences

ImmunityBio 10-Q: Q3 Revenue $48.7M, $334.3M Cash, Going-Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.59
Mkt Cap
$9.152B
52W Low
$1.95
52W High
$12.43
52W Position info
289% above low
Off High info
39% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.95.

Summary

ImmunityBio's Q3 10-Q shows revenue up 53% to $48.7 million and $334.3 million in cash, but includes an explicit going-concern warning and a $1.05 billion nine-month loss that is mostly non-cash remeasurement of its related-party note and warrants.


Key Events · Earnings and Guidance · IBRX

  • Q3 Revenue Up 53% to $48.7M

    Net product revenue reached $48.7 million versus $31.8 million a year earlier; nine-month revenue was $143.6 million, up 92% from $74.7 million.

  • Going-Concern Warning Restated

    Management states substantial doubt exists about the ability to continue as a going concern without additional funding, relying on cash, product sales, equity issuance and loans from affiliates to fund the next 12 months.

  • $1.05B Loss Is Mostly Non-Cash

    The nine-month net loss of $1,047.8 million includes a $393.2 million non-cash change in fair value of the related-party convertible note and a $355.4 million non-cash change in fair value of warrant liabilities — mark-to-market moves tied to the share price, not cash outflows or new dilution.

  • Balance Sheet: $334.3M Cash vs $1.75B Liabilities

    Cash, equivalents and marketable securities totaled $334.3 million at September 30, 2026, against total liabilities of $1,754.8 million and a stockholders' deficit of $1,145.4 million; the $480.0 million related-party note matures December 2027.


Analysis · IBRX · Life Sciences

Revenue growth is real — Q3 net product revenue of $48.7 million is up 53% and the nine-month total of $143.6 million is up 92% — but the company still burns cash and says substantial doubt exists about its ability to continue as a going concern without more funding. The $1.05 billion nine-month net loss is mostly accounting: $393.2 million from remeasuring the related-party convertible note and $355.4 million from remeasuring warrant liabilities, both non-cash and both driven by a higher share price, not by operations. What actually matters is the balance sheet: $334.3 million of cash and securities against $1.75 billion of liabilities, a $480.0 million related-party note due December 2027, and a revenue interest obligation to Oberland that now stands at $426.3 million. The ATM has $319.9 million left and warrants keep getting exercised for cash, so the funding question is manageable near term — but it is still being answered by selling stock, not by the P&L.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IBRX was trading at $7.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.08 info
Change: -$2.01 (-25%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.08 info
Change: -$2.76 (-31%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $6.08 info
Change: -$2.68 (-31%) info
Market Cap: $6.404B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.08 info
Change: -$3.34 (-35%) info
Market Cap: $6.404B info
IBRX
Oct 14, 2026, 11:31 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $9.74
Real-time Price: $6.08 info
Change: -$3.66 (-38%) info
Market Cap: $6.404B info